US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree


The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs)…

Antibiotics and Infectious diseasesDaiichi SankyoDiabetesGenericsNorth AmericaRanbaxy LaboratoriesRegulation

Ranbaxy to market four drugs for Daiichi Sankyo in Singapore


Japan’s second largest drugmaker, Daiichi Sankyo TYO: 4568), has announced the start of synergistic…

Antibiotics and Infectious diseasesAsia-PacificCravitDaiichi SankyoMarkets & MarketingPharmaceuticalRanbaxy Laboratories

Ranbaxy and Merck & Co drop co-development of anti-infectives


US drug giant Merck & Co (NYSE: MRK) has terminated its nearly two year-old alliance with India’s…

Antibiotics and Infectious diseasesMerck & CoPharmaceuticalRanbaxy LaboratoriesResearch

Daiichi Sankyo to leverage Ranbaxy’s Romania and South Africa presence to market Tavanic


Japanese drug major Daiichi Sankyo says it plans to leverage its 64%-owned Indian affiliate Ranbaxy Laboratories’…

Antibiotics and Infectious diseasesDaiichi SankyoEuropeLicensingMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesRest of the WorldSanofi-AventisTavanic

Ranbaxy launches Lulifin, in-licensed from Summit Pharmaceuticals, in India


Indian drug maker Ranbaxy Laboratories, which is majority owned by Japan’s Daiichi Sankyo, has launched…

Antibiotics and Infectious diseasesAsia-PacificDaiichi SankyoDermatologicalsPharmaceuticalRanbaxy LaboratoriesSankyo

Back to top